Mesothelioma Help Cancer News
After Losing Father to Mesothelioma, Mother Finds It “Unspeakable” That Asbestos Is Found In Children’s Makeup
As a mother, I worry. I worry about my daughter’s first day of school; will she be nervous? I wonder what the world will be like for her as she grows and moves into adulthood. I wonder what she will decide to be when she grows up, who will she grow up to be? Something that I never considered worrying about until my father got sick was the danger of asbestos.
Sure, we know that asbestos is found in building products and things of that nature, but it being used in children’s crayons and makeup? It is completely unspeakable and inexcusable. Why would a company knowingly place our youth in danger, all for the sake of making a dollar?
Yes, I know that the products have been removed from the shelves, but who is to say that there aren’t more items like these still out there, let alone the damage that may have already been done? Thinking about what these children may end up going through because they colored a picture or played dress up makes me angry and sick to my stomach.
It’s time that we all stand up to the companies endangering society at large, especially those targeting our children. It is not okay to ignore the deadly implications of asbestos, enabling more and more of us to be put, unknowingly, at risk.
Take the time to look at ingredients of items you may use every day. If it’s questionable, put it back, call the company and demand answers. You owe it to yourself and to future generations to stop this cycle and help to eradicate the use of asbestos, and, in turn, mesothelioma.
Chemical in Alaskan Sea Sponge May Kill Mesothelioma Cancer Cells
Another sea-dwelling plant is making headlines in oncology research. Over a year ago MesotheliomaHelp reported that the active agent, trabectedin, found in the Caribbean sea cucumber showed promise in fighting mesothelioma. Now, researchers believe the unique chemical composition in the deep-water Alaska green sponge could kill cancer cells. This discovery could lead to treatments for pancreatic cancer, and other aggressive cancers such as mesothelioma.
Found by National Oceanic and Atmospheric Administration (NOAA) scientist Bob Stone in 2005 during a fishery mission, the sponge has researchers from around the U.S., and the globe, clamoring to find out more about it, according to a July article in NOAA Fisheries. A researcher from the Medical University of South Carolina, who has been turning to marine life as a potential drug ingredient for nearly 20 years, is particularly excited by the discovery and is now working with Stone, a team in New Zealand, and with other cancer centers in the U.S.
Identifying the sponge as Latrunculia austini, Mark Hamann, the Charles and Carol Cooper SmartState Endowed Chair at MUSC, said that the plant, “covers unique and unprecedented chemical space.”
Samples of the sponge are now in the hands of researchers at the Henry Ford Cancer Institute where a team is testing sponge extracts against pancreatic cancer cells. The researchers found the green sponge extracts effective in killing pancreatic cancer cells in the lab.
“You’d never look at this sponge and think this is a miracle sponge, but it could be,” said Stone.
Although pancreatic cancer and mesothelioma are very different cancers, the two diseases both lack treatments that can effectively combat the tumors. Chemotherapy is a standard treatment option for both mesothelioma and pancreatic cancer, but eventually the cancer cells build up a resistance to the treatment. Survival is low for both cancers.
The cancer-fighting capability of the sponge is driven by its inability to flee from predators. As a result, it builds up powerful chemicals to ward off its enemies. For that reason, Hamann and the other researchers turn to these marine creatures to develop life-saving drugs. They note that “Of the eight most frequently prescribed products to treat cancer, half are natural products.”
The sponge is at a depth that makes it difficult to harvest bringing a significant obstacle to the research, albeit one worth trying to overcome. “For pancreatic cancer this is absolutely the best lead that we have,” Hamann said.
Mesothelioma, caused by asbestos exposure, is diagnosed in close to 3,000 Americans each year. Currently, there is no cure for the disease, but research into treatments of other cancers is followed closely by the mesothelioma community in hopes the results are transferrable.
“Given the lack of current effective drug treatments available for pancreatic cancer, this study finding offers hope for the future of cancer care,” said Fred Valeriote, senior researcher with the Henry Ford Cancer Institute.
This research is in early stages and significant, additional research is still needed.
Photo Credit: NOAA Fisheries
Combination of Liquid Biopsy Tools Improves Results in Detecting Biomarkers, May Lead to Better Selection of Targeted Mesothelioma Treatments
Researchers continue to look for an effective tool that can be used for the early detection of cancer and to track the effectiveness of treatment. Now, one company reports that by pairing its liquid biopsy analyzer tool with another company’s genetic data analysis tool, the resulting tests proved to be nearly 100% accurate. This is another step in using blood tests to help guide personalized medicine for lung cancer and pleural mesothelioma patients.
In a press release prior to the Fifth AACR-IASLC International Joint Conference held earlier this month in San Diego, Biocept, Inc, reports when it paired the Target Selector ctDNA lung cancer assays with the Thermo Fisher QuantStudio5 (QS5) real-time PCR instrument results of the detection of key lung cancer mutations resulted in “more than 99% sensitivity and more than 99% specificity.”
“The ability to rapidly and accurately assess the molecular status of a patient’s tumor using a simple blood draw can be a critical factor in the selection of individualized targeted therapy,” said Biocept’s Senior Vice President and Senior Medical Director Veena Singh, MD. “Our tests can further provide for the monitoring of response to therapy over time without invasive tissue biopsies that can be difficult to perform in patients diagnosed with cancer.”
The tests targeted EGFR, KRAS and BRAF mutations that have been shown to be present in lung cancer and in some pleural mesothelioma tumors as well. According to some reports, mutations of the KRAS gene (Kirsten rat sarcoma viral oncogene homolog) are found in 20 to 25 percent of lung cancers. The EGFR gene is overexpressed in more than 50% of pleural mesothelioma patients, and in approximately 15% of lung cancer patients, and is one of the primary targets for bringing personalized care to cancer patients.
With the advent of personalized therapies that target specific biomarkers, ensuring that effective tools are available to quickly and easily identify treatable mesothelioma markers is critical. Personalized cancer treatment optimizes the potential for success.
Often, lung cancer and mesothelioma patients must undergo invasive and painful biopsies to extract diseased tissue for diagnosis. Tissue biopsy tests can take up to 10 days to get a result leaving patients worried and missing out on treatment. However, with just a blood sample, this partnership could bring effective treatments to cancer patients in a shorter time.
Pleural mesothelioma, caused by exposure to airborne asbestos fibers, is an incurable cancer involving the lining of the lung. Nearly 3,000 Americans are diagnosed with mesothelioma each year. There is no cure for the cancer.
Mesothelioma Drug Given Promising Innovative Medicine Status in the UK
Boehringer Ingelheim has announced that the UK is following in the footsteps of the U.S. in the latest designation for the company’s drug nintedanib. In December 2016, the U.S. Food and Drug Administration granted orphan drug designation to the investigational cancer drug for the treatment of mesothelioma. Now, the UK Medicine and Healthcare Products Regulatory Agency has designated nintedanib a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma.
The PIM designation, according to Gov.UK, is an indication that the product may be eligible for the early access to medicines scheme (EAMS) that brings medicines to patients with life threatening conditions when there is an unmet medical need. The designation was assigned based on the encouraging results of the phase II/III LUME-Meso trial, according to a Jan. 4 PharmaTimes article.
“This is fantastic news and the right decision taking into account the risk/benefit profile of nintedanib from a very credible Phase II trial,” said Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and University Hospitals of Leicester NHS Trust, UK, commenting on the decision.
Results from the LUME-Meso Trial showed “statistically significant improvements,” according to Pharma Times, with mesothelioma patients treated with the drug plus chemotherapy achieving 9.4 months of progression free survival compared to 4.7 months for those patients receiving chemotherapy alone.
Nearly 2,500 cases of pleural mesothelioma are diagnosed each year in the UK. With limited effective treatment options the median survival is less than 14 months. Reports indicate that nearly 3,000 Americans are also diagnosed with the deadly cancer each year. New, effective treatments are critically important to improve mesothelioma patient survival.
To find out more about the LUME-Meso trial, see ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/results?term=%22malignant+mesothelioma%22&recr=Open&pg=1
Sources :
- U.S. Food and Drug Administration
http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-announces-fda-acceptance-review-mk-3475-biologics-license-appli - Gov.UK
https://www.gov.uk/government/news/medical-innovation-doctors-and-patients-encouraged-to-give-views - PharmaTimes
http://www.pharmatimes.com/news/pim_status_for_boehringers_mesothelioma_drug_1215220
Nurse Discusses Importance of Pneumonia Vaccine for Mesothelioma Patients and Their Caregivers
People diagnosed with malignant mesothelioma undergo medical treatments that can compromise their already weakened immune system. This leaves them even more susceptible to developing additional illnesses such as pneumonia or the flu. When being treated at a mesothelioma center, immunizations are offered to patients before they start their treatments to help prevent them from getting sicker. These vaccines are usually administered two weeks prior to starting treatments.
Pneumonia is a specific type of lung infection that inflames the air sacs in the lung and causes them to fill with fluid or purulent material. Pneumonia can be caused by bacteria, viruses, or fungi. There is a vaccination for the most common cause of bacterial pneumonia in the U.S., which is caused by the streptococcus bacteria.
The symptoms of pneumonia can be mild to severe depending on the organism involved, your age, and your overall health. Some of the common symptoms of pneumonia are the same as those of a cold or the flu, but tend to last longer. Chest pain when breathing or coughing, a productive cough, fatigue, fever, sweating, shaking chills, shortness of breath, nausea, vomiting or diarrhea are all possible symptoms of pneumonia.
Most kinds of pneumonia are contagious. Both viral and bacterial pneumonia can be spread by inhaling airborne droplets from a sneeze or a cough. It is estimated that about 900,000 Americans get pneumococcal pneumonia every year, and about 5-7% of those infected die from the illness.
Vaccinations for pneumococcal diseases are recommended for all adults over age 65. There are two kinds of pneumococcal vaccines available in the U.S.: Pneumococcal conjugate vaccine- PCV13 or Prevnar13, and Pneumococcal polysaccharide vaccine- PPSV23 or Pneumovax. PCV13 is recommended for all children younger than 2 years old, all adults 65 years or older who have not been previously, and some people with certain medical conditions. PPSV23 is recommended for all adults 65 years old and older, for some people of any age who have certain medical conditions, and for adults who smoke. PPSV23 is recommended to be given at least one year after the dose of PCV13 or Prevnar13.
The pneumococcal vaccine can protect against other diseases caused by the pneumococcal bacteria, such as meningitis, ear and sinus infections, as well as blood poisoning or sepsis. Pneumonia can affect anyone, but two groups are at the highest risk are children aged two or younger, and people aged 65 or older. Anyone who may have a weakened immune system, like mesothelioma patients, are also at risk.
Any caregiver over age 65 should check with their physician about getting vaccinated. Other caregivers who smoke or have other chronic conditions should also check with their physicians about getting the vaccination.
Caregivers need to be reminded that they need to care for themselves as well as their loved ones during this stressful time.
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now